{"schema_version":"secwatch.filing_event.v1","accession":"0001438533-23-000023","form_type":"8-K","ticker":"TVTX","cik":"0001438533","company_name":"Travere Therapeutics, Inc.","filed_at":"2023-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.876699+00:00","generated_at":"2026-06-15T21:34:07.039050+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Travere Q1 net loss $86.3M; FILSPARI launch nets $3M in 6 weeks","bullets":["Net product sales $50.3M (incl. $3M FILSPARI), up from $46.4M YoY; net loss $86.3M ($1.27/share) vs $76M ($1.20).","Cash $561.5M after $216M stock offering and $23M milestone to Ligand for FILSPARI approval.","FILSPARI launched week of Feb 27; 146 new patient start forms received in first 6 weeks.","Phase 3 DUPLEX in FSGS missed primary eGFR slope endpoint; company to engage regulators on path forward.","EMA decision on sparsentan for IgAN expected H2 2023; PROTECT confirmatory data due Q4 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001438533-23-000023","json":"https://secwatch.observer/filing/0001438533-23-000023.json","markdown":"https://secwatch.observer/filing/0001438533-23-000023.md","text":"https://secwatch.observer/filing/0001438533-23-000023.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1438533/000143853323000023/0001438533-23-000023-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1438533/000143853323000023/tvtx-20230504.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T21:34:07.039050+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d050285abbf8b76dc2c10294bd80558d56cfc46a","claim":"Travere Therapeutics, Inc. reported the quarter ended March 31, 2023 results: revenue $57.0 million, net income $86.3 million, EPS $1.27 per basic share.","evidence_excerpt":"IgAN in Europe expected in second half 2023 • Net product sales of FILSPARI totaled $3.0 million for the first quarter of 2023 • Total revenue for the first quarter of 2023 was $57.0 million, consisting of $50.3 million in net product sales and $6.7 million in licensing and collaboration revenue • Cash, cash equivalents, and marketable securities, as of March 31,","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1438533/000143853323000023/0001438533-23-000023-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2023"},{"label":"Revenue","value":"$57.0 million"},{"label":"Net income","value":"$86.3 million"},{"label":"EPS","value":"$1.27 per basic share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}